Published in J Invest Dermatol on June 09, 2011
Angiotropism, pericytic mimicry and extravascular migratory metastasis in melanoma: an alternative to intravascular cancer dissemination. Cancer Microenviron (2014) 0.90
Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther (2012) 0.89
Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther (2012) 0.89
Dioxin receptor regulates aldehyde dehydrogenase to block melanoma tumorigenesis and metastasis. Mol Cancer (2015) 0.84
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82
Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma. Cancer Res (2015) 0.82
Paracrine signaling between carcinoma cells and mesenchymal stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discov (2012) 0.80
Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma. Gene Ther (2014) 0.79
Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways. Sci Rep (2016) 0.78
Understanding melanoma stem cells. Melanoma Manag (2015) 0.77
Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches. Oncoimmunology (2012) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
Identification of cells initiating human melanomas. Nature (2008) 8.28
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell (2007) 6.04
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell (2007) 4.34
Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell (1992) 4.26
Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell (1991) 3.95
Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer (2007) 3.80
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A (2009) 2.95
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev (2011) 2.56
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res (2008) 1.99
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res (2010) 1.50
Selection of tumorigenic melanoma cells using ALDH. J Invest Dermatol (2010) 1.27
Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene (2010) 1.26
Mitogenic activity of laminin on human melanoma and melanocytes: different signal requirements and role of beta 1 integrins. Cancer Res (1995) 1.05
Melanoma stem cells--are there devils in the detail? Pigment Cell Melanoma Res (2010) 0.78
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res (2005) 1.76
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell (2010) 1.76
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest (2008) 1.69
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol (2002) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res (2010) 1.52
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc (2012) 1.51
Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci (2010) 1.48
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Cleavage of MCM2 licensing protein fosters senescence in human keratinocytes. Cell Cycle (2008) 1.42
Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am J Pathol (2007) 1.41
Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A (2010) 1.37
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res (2007) 1.37
Melanoma stem cells: the dark seed of melanoma. J Clin Oncol (2008) 1.37
Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res (2009) 1.36
The role of altered cell-cell communication in melanoma progression. J Mol Histol (2004) 1.34
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology (2008) 1.34
A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res (2011) 1.33
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. FASEB J (2002) 1.31
Melanoma development and progression: a conspiracy between tumor and host. Differentiation (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. Gastroenterology (2010) 1.29
Normal human melanocyte homeostasis as a paradigm for understanding melanoma. J Investig Dermatol Symp Proc (2005) 1.28
CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol (2006) 1.27
Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells (2006) 1.27
Melanoma and the tumor microenvironment. Curr Oncol Rep (2008) 1.26
Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res (2011) 1.24
Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene (2003) 1.23
Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol (2003) 1.19
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB J (2006) 1.17
Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis (2010) 1.17
Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell (2012) 1.17
Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm (2011) 1.17
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type II diabetic wounds. Wound Repair Regen (2004) 1.16
Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res (2011) 1.14
The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res (2008) 1.14
A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res (2013) 1.14
Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci (2005) 1.13
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol (2002) 1.11
Recent advances in melanoma biology. Oncologist (2004) 1.10
Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem Biol (2008) 1.09
Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev (2005) 1.08
Reciprocal regulation of MelCAM and AKT in human melanoma. Oncogene (2003) 1.08
The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res (2013) 1.06
Loss of EphB6 expression in metastatic melanoma. Int J Oncol (2003) 1.06
Functional erythropoietin autocrine loop in melanoma. Am J Pathol (2005) 1.06
CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol (2005) 1.03
Cancer stem cells are everywhere. Nat Med (2009) 1.03
Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol (2007) 1.03
In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin Drug Discov (2008) 1.03
Permissive environment in postnatal wounds induced by adenoviral-mediated overexpression of the anti-inflammatory cytokine interleukin-10 prevents scar formation. Wound Repair Regen (2007) 1.03